Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | NPC1 | O15118 | 4/20 | 0.80 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.66 |
| ▸ | CDK2 | P24941 | 4/20 | 0.66 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.65 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | TUBB8B | A6NNZ2 | 1/20 | 0.60 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.60 |
| ▸ | TUBB | P07437 | 1/20 | 0.60 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.60 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.60 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.60 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.60 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.60 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.60 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.60 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25610865 | 0.90 | MEN1 (0.80) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL23929856 | 0.90 | CDK5 (0.80) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL20142856 | 0.89 | MEN1 (1.00) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL25609654 | 0.89 | MEN1 (1.00) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL25609733 | 0.89 | MEN1 (0.78) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL27199997 | 0.88 | MEN1 (0.77) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL23929747 | 0.87 | MEN1 (0.75) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL13633841 | 0.86 | CCNA2 (0.88) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL23929761 | 0.85 | MEN1 (0.73) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL23929788 | 0.84 | MEN1 (0.71) | MEN1KMT2ANPC1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| EP-4139286-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115697980-A | Substituted aminothiazoles as DGKZETA inhibitors for immune activation | 拜耳公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021214019-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | MEN1 4344/4885KMT2A 1150/4885NPC1 3336/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | MEN1 4344/4885KMT2A 1150/4885NPC1 3336/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | MEN1 4344/4885KMT2A 1150/4885NPC1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.